ATSATS
Recorded

ATS 26th Annual Scotiabank Transportation & Industrials Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration31 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Jonathan GoldmanAnalyst

Good morning. I think we'll get started. My name is Jonathan Goldman, if we haven't met, Diversified Industrials Analyst at Scotiabank. I'm pleased to welcome our next company, ATS Corporation. I think everyone may have known them already, a global leader in automation solutions. I'm pleased to welcome from ATS Chief Executive Officer Doug Wright and Chief Financial Officer Anne Cybulski. Thanks for joining us. Thanks, Jonathan.

Jonathan GoldmanAnalyst

Nice to be here. I think everyone knows you by this time, Doug.

Jonathan GoldmanAnalyst

You've been here already in the seat now for about, I guess, coming up on a year. So maybe we can take a step back and think about the business, where it's been this year since you've been there. Maybe we can start with a recap of fiscal Q2. You kind of took out the revenue growth targets, the margin targets this year, kind of a bit of a tougher ramp to revenue. So maybe we can just start there, what you've observed in your first, call it, 10, 11 months on the job, what you didn't expect, what you did expect, what's surprising you, positive, negatively, and maybe just level set us on where the business is today.

Doug WrightCEO

Okay. I think the short-term issue that we had in Q2 was, and the reason we removed our second half guidance is that we had a surprise with the Section 338 tariffs, which affected a significant portion of our business. We are working through that with our customers now, and we will hopefully resolve that in the second half, but it clearly creates enough uncertainty that, and the scale and the margin of that business are such that it does have a material impact. I think in the medium term, that will normalize. There is no share loss or any change in intention for the need for the infrastructure, but it is just a bit of a, unfortunately, politics kind of caught us offside there.

Doug WrightCEO

I think in terms of my impressions over the last, my first 10, 11 months on the job now, I think we have a really strong franchise along a number of really exciting markets. I think our life sciences position is robust. We have had the short-term headlines around the roll-down of GLP-1, I think is temporary, and I think our non-GLP-1 business in life sciences is a high single-digit grower this year, and we expect that to be the sustained rate going forward. The comps on GLP-1, it is a little bit of a two edges of the sword.

Doug WrightCEO

We were the beneficiary of being kind of first to market with the two major players in that market in the very beginning of that therapy coming to market, and we are still building those systems, but the orders a couple of years ago were starting to affect our revenue, and it has been taking us a while to build back the backlog. The exciting part about Q2 was that we had a really strong orders growth, and it was in life sciences, and it was not radiopharma.

Doug WrightCEO

Radiopharma was part of it, but we also had some restored growth in orders in some of our more traditional med device business, because we have been spending a lot of time to diversify the pipeline of activities in life sciences specifically to make us more resilient to single therapy dynamics, and that has allowed us to create a, whether it is diabetes care, vision care, we have a new product to do automated visual inspection of vaccines. There is a lot of new slices of the pie, if you will, in the pipeline that is starting to mature, and that is why we had a significant growth in the quarter in orders. It was not one thing. It was across, frankly, it was within radiopharma as well as in a traditional med device platform. We feel pretty good about the midterm growth.

Doug WrightCEO

We've got some dynamics in this quarter that are related to the order cycle that we had in Q2. It's a little bit odd because we had really strong orders velocity in Q2, but the timing of those is such that it's not going to be supportive of a significant growth in Q3. It's a little further dated out, so that's a little bit of the unfortunate nature, and that's probably, to answer your initial question, why we felt like we needed to signal that the uncertainty in the second half was real. That doesn't take away from the fact that in the midterm, we've got a lot of growth potential in front of us.

Anne CybulskiCFO

One thing that we've talked about before, but over the cycle, we do expect our growth to be in the mid to high single digits, and we've shown that, depending on the time period you choose. More recently, we've kind of come out from under the EV situation. We have this GLP-1 capacity buyout that Doug talked about, but over the cycle, we do expect to drive that level of growth, and with the work that we're putting in now to diversify the funnel and go into some new areas that we, from a technology perspective, that we have really good strength in, we see that our ability to deliver on that over the medium to long term.

Jonathan GoldmanAnalyst

Okay, there's lots to unpack there. Maybe if we just think about the automation industry generally, peers, you'll tell me they're not peers, but generally, that industry is growing in mid-single digits. I think in the past, ATS has talked about growing above those markets. Maybe you can talk about, you just kind of gave kind of a mark there on what you're thinking. How much of it is project versus not project-based? How much of it is the dynamic that we're seeing in the growth is just lapping those trends in EVs or GLP-1s? But I guess I'm more interested in the different streams of diversification you're thinking about in revenue. I mean, radiopharma's come up a lot in the calls, and you're excited about that, but it does seem like the bookings trend in fiscal Q2 were also positive in other parts of the business.

Jonathan GoldmanAnalyst

Maybe we can start with the life sciences, then we can go into the other segments and maybe the services piece as well.

Doug WrightCEO

Yeah, I think on the general growth question, I think because we are more heavily oriented toward, call it first-generation CapEx in a number of, particularly in life sciences, I mean, we are fortunate that we have very strong connectivity, direct connectivity with tier 1 players in these markets, and we get exposed to their new therapies as they're coming to market. We do have this sort of lumpiness that comes with being in that particular part of the ecosystem, because it's both CapEx and life sciences CapEx, which traditionally has more of a boom. You get a big boom of growth when a therapy is announced, and then it becomes a difficult comp the year after that.

Doug WrightCEO

I think part of it is just the nature of, we're in position for first-generation technologies, whether it's GLP-1 or the next generation radio-oncology therapies. We are present at the very edge of the new technology as it comes to market. That exposes us a little more than some of our contemporaries to sort of the CapEx cycles. I think if you look at the long-term growth of ATS, if you look at sort of 10-year, five-year horizon, we're very much in that mid to high single-digit organic growth rate. I think in the short term, if you're going to compare us to someone like a, I don't know, a Rockwell, who's a partner, a supplier and a partner, they have a much smoother revenue profile because they're much more exposed to the broader ecosystem, and we're more nichey, if you will. We're more concentrated. That has the effect of having some years where we're going to outgrow the market and some years aren't.

Doug WrightCEO

The long-term mean is probably in line with slightly ahead of those comps because we're smaller, but we're going to have a different amplitude. I think in terms of what we're doing to offset it, there are really two things. The first is diversification of the sub-market. So within life sciences, to stay in life sciences, we have diversified our approach. We're now developing, or have developed and are shipping sterilization systems, automated visual inspection systems for vaccine inspection and quality, next generation of diabetes care, continuous glucose monitors, which have now migrated from being a diabetes care to being a wellness device. We're building out our portfolio, and what's happening really is we're taking technology elements that we've developed on the front end of our business.

Doug WrightCEO

How to use cameras and vision systems and AI to inspect a vaccine can now be applied to other visual inspection technologies. Actually, where that visual technology for inspecting vaccines came from was our learning about how to do it for continuous glucose monitors, where you have to inspect the insertion needle and the sensor in a very, very precise way. We have these core technology building blocks that we've developed for our first-of-a-kind segments of our market, and now we're diversifying that into other elements of the life sciences industry. Because once you have an ability to serve an FDA-regulated med device market and you get a reputation with those players, to migrate to other customers and bring that technology to them is something that's proven to be.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day